FMP
Histogen Inc.
HSTO
NASDAQ
Inactive Equity
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
0.02 USD
0 (0%)
HSTO Financial Statements
Quarter
2023 Q3
2023 Q2
2023 Q1
2022 Q4
Total Revenue
5k
5k
5k
4k
Cost of Revenue
62k
38k
38k
38k
Gross Profit
-57k
-33k
-33k
-34k
Operating Expenses
3.53M
2.09M
3.48M
2.97M
Research and Development
660k
536k
993k
1.09M
Selling, General & Administrative Expenses
2.87M
1.56M
2.49M
1.88M
Selling & Marketing Expenses
0
0
0
0
General & Administrative Expenses
2.87M
1.56M
2.49M
1.88M
Other Expenses
0
0
0
0
Operating Income
-3.52M
-2.09M
-3.47M
-2.97M
Total Other Income/Expenses Net
-329k
-1k
0
1k
Income Before Tax
-3.85M
-2.09M
-3.47M
-2.97M
Income Tax
0
3k
-1k
20k
Net Income
-3.85M
-2.09M
-3.47M
-2.99M
Basic EPS
-0.9
-0.49
-0.81
-0.93
EPS Diluted
-0.9
-0.49
-0.81
-0.93
Basic Average Shares
4.27M
4.27M
4.27M
3.21M
Diluted Average Shares
4.27M
4.27M
4.27M
3.21M
EBITDA
-3.79M
-2.05M
-3.44M
-2.93M
Retained Earning Schedule
Quarter
2023 Q3
2023 Q2
2023 Q1
2022 Q4
Retained Earnings (Previous Year)
-93.83M
-91.74M
-88.27M
-85.31M
Net Income
-3.85M
-2.09M
-3.47M
-2.99M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-97.69M
-93.83M
-91.74M
-88.27M
Other Distributions
-3.85M
-2.09M
-3.47M
-2.96M
PPE Schedule
Quarter
2023 Q3
2023 Q2
2023 Q1
2022 Q4
Gross PPE
0
4.85M
4.97M
5.09M
Annual Depreciation
62k
38k
38k
38k
Capital Expenditure
0
0
0
-1k
Net PPE
-62k
4.81M
4.94M
5.06M
Intangible and Goodwill Schedule
Quarter
2023 Q3
2023 Q2
2023 Q1
2022 Q4
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
